PT - JOURNAL ARTICLE AU - Colavita, Francesca AU - Meschi, Silvia AU - Maria Gruber, Cesare Ernesto AU - Rueca, Martina AU - Vairo, Francesco AU - Matusali, Giulia AU - Lapa, Daniele AU - Giombini, Emanuela AU - Carli, Gabriella De AU - Spaziante, Martina AU - Messina, Francesco AU - Bonfiglio, Giulia AU - Carletti, Fabrizio AU - Lalle, Eleonora AU - Fabeni, Lavinia AU - Berno, Giulia AU - Puro, Vincenzo AU - Caro, Antonino Di AU - Bartolini, Barbara AU - Ippolito, Giuseppe AU - Capobianchi, Maria Rosaria AU - Castilletti, Concetta AU - , TI - Virological and Serological Characterization of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination AID - 10.1101/2021.09.21.21263882 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.21.21263882 4099 - http://medrxiv.org/content/early/2021/09/22/2021.09.21.21263882.short 4100 - http://medrxiv.org/content/early/2021/09/22/2021.09.21.21263882.full AB - Coronavirus disease 2019 (COVID-19) vaccines are proving to be very effective in preventing severe illness; however, although rare, post-vaccine infections have been reported. The present study describes 94 infections (47.9% symptomatic, 52.1% asymptomatic), occurred in Lazio Region (Central Italy) in the first trimester 2021, after first or second dose of mRNA BNT162b2 vaccine. Median viral load at diagnosis was independent from number and time of vaccine dose administration, despite the higher proportion of samples with low viral load observed in fully vaccinated individuals. More importantly, infectious virus was cultured from NPS collected from both asymptomatic and symptomatic vaccinated individuals, suggesting that, at least in principle, they can transmit the infection to susceptible people. The majority of the post-vaccine infections here reported, showed pauci/asymptomatic clinical course, confirming the impact of vaccination on COVID-19 disease. Most cases (78%) showed infection in presence of neutralizing antibodies at the time of infection diagnosis, presumably attributable to vaccination, due to the concomitant absence of anti-N IgG in most cases. The proportion of post-vaccine infections attributed either to Alpha and Gamma VOCs was similar to the proportion observed in the contemporary unvaccinated population in Lazio region. In addition, mutational analysis did not suggest enrichment of a defined set of Spike protein substitutions depending on the vaccination status. Characterization of host and virus factors associated with vaccine breakthrough, coupled with intensive and continuous monitoring of involved viral strains, is crucial to adopt informed vaccination strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by funds to the Istituto Nazionale per le Malattie Infettive (INMI) Lazzaro Spallanzani IRCCS, Rome (Italy), from Ministero della Salute (Programma CCM 2020; Ricerca Corrente, linea 1; COVID 2020 12371817); the European Commission, Horizon 2020 (EU project 101003544, CoNVat; EU project 101005111, DECISION; EU project 101005075, KRONO) and the European Virus Archive, GLOBAL (grants no. 653316 and no. 871029).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was performed within the framework of the COVID-19 outbreak response and surveillance program. Use of laboratory and epidemiological records for research purpose has been approved by the INMI Ethical Committee (issue n. 214/20-11-2020), and the need of informed consent form was waived. The study has been conducted in respect of current legislation on personal data protection, all data are presented in non-identifiable form.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequencing data that support the findings of this study have been deposited in GISAID; the list of the accession codes is available from the corresponding author on reasonable request. The other data used and/or analyzed during the current study are available, only for sections non-infringing personal information, from the corresponding author upon request.